Gareth R Tibbs is a notable inventor based in Staten Island, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target HCN channels. With a total of 2 patents to his name, his work has the potential to impact the treatment of various HCN-related disorders.

Latest Patents

Gareth's latest patents include innovative compounds that serve as HCN1 antagonists. These compounds, represented by Formula (I) and Formula (II), are designed to modulate HCN channels, which are crucial intermembrane proteins functioning as nonselective voltage-gated cation channels in the plasma membranes of heart and brain cells. The patents also detail pharmaceutical compositions and kits that incorporate these compounds, along with methods for treating HCN-related disorders, such as pain, by administering the described compounds and compositions.

Career Highlights

Gareth R Tibbs is affiliated with Cornell University, where he continues to advance his research and development efforts. His work is characterized by a strong focus on innovative solutions in the pharmaceutical industry, particularly in the realm of pain management and neurological health.

Collaborations

Some of Gareth's notable coworkers include Peter A Goldstein and Anthony A Sauve. Their collaborative efforts contribute to the ongoing research and development of groundbreaking pharmaceutical solutions.

Conclusion

Gareth R Tibbs exemplifies the spirit of innovation in the pharmaceutical field, with his patents paving the way for new treatments for HCN-related disorders. His contributions are significant and reflect a commitment to improving health outcomes through scientific advancement.